39.73USD+5.33%Mkt Cap: 1.91B USDP/E: —Last update: 2026-05-26
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous sy…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.91B USD
Enterprise Value1.29B USD
Revenue (TTM)20.00M USD
Gross Profit6.86M USD
Net Income (TTM)-111.48M USD
Revenue/Share0.4770 USD
Last Price39.73 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees84
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.21
PEG—
EV/EBITDA-10.64
EV/Revenue64.46
P/S87.76
P/B3.72
EPS (TTM)-2.60
EPS (Forward)-4.47
52W Range
7.73093% of range42.27
52W High42.27 USD
52W Low7.730 USD
Profitability
Gross Margin34.28%
Oper. Margin-121.08%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.00%
ROA-21.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-87.47M USD
CapEx (TTM)616.00K USD
FCF Margin-247.16%
FCF Yield-2.59%
Net Debt-465.98M USD
Net Debt/EBITDA3.84
Balance Sheet
Debt/Equity0.02
Current Ratio27.08
Quick Ratio26.64
Book Value/Sh9.863 USD
Cash/Share9.969 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)55.90 USD
Target Range40.00 USD – 80.00 USD
# Analysts10
Ownership
Shares Out.47.83M
Float31.34M
Insiders4.65%
Institutions109.26%
Short Interest
Short Ratio8.9d
Short % Float10.11%
Short % Out.6.38%
Shares Short3.05M
Short (prev mo.)3.85M
Technical
SMA 5033.67 (+18.0%)
SMA 20027.80 (+42.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)361.80K
Avg Vol (10d)312.73K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—